source
- Astellas signs up to $1.34 billion option deal for Audax's DAX-044 immuno-oncology candidateAstellas Pharma announced it will pay up to $1.34 billion for an exclusive option to license Audax Biosciences' investigational antibody-cytokine fusion, DAX-044. The agreement includes an undiscl…
- Astellas commits up to $285M upfront for Audax's preclinical IL-12 program, with potential $1.05B milestonesAstellas Pharma has entered a licensing agreement with Audax Biosciences to gain rights to the latter’s IL-12 immuno‑oncology candidate DAX‑044. Under the deal, Astellas will pay up to $285 millio…